Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
NCT05253846Phase 2Active, not recruiting
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer, sponsored by Gruppo Oncologico Nord Ovest. Primary endpoint: Complete Pathologic Response at 30 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05253846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253846.